Compare Kroger Co (KR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Summit Therapeutics Inc — how do they compare? Kroger Co trades at $56.01 (market cap $34.46B), while Summit Therapeutics Inc trades at $15.27 (market cap $12.06B). The key difference: Kroger Co is far larger — about 2.9× Summit Therapeutics Inc's market cap, and Kroger Co pays a 2.56% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KR | SMMT | |
|---|---|---|
Market Cap | $34.46B | $12.06B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $26.98 |
52-Week Low | $55.53 | $12.55 |
Enterprise Value | $54.56B | $11.39B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.48, down 0.44% on the day, with a bearish technical signal driven by moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but maintains a strong cash flow position with $2.08B net cash flow in 2025. Recent corporate actions include dividend payments, and news highlights e-commerce leadership changes and product recalls.
The outlook is balanced; analyst consensus is a Buy with a $68.25 price target, implying 21% upside, supported by stable revenue and margin expansion. Risks include competitive pressures, debt increase, and operational challenges from recent recalls. The stock offers value with a low P/S ratio but faces near-term technical headwinds.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
